EVLP Technology Facilitates Transplantation of Marginal Lungs in UK Hospitals

In recent years, the demand for lung transplants has significantly outpaced the availability of suitable donor organs. This disparity has left many patients on waiting lists, with some succumbing to their illnesses before a viable organ becomes available. However, a groundbreaking technology known as Ex Vivo Lung Perfusion (EVLP) is revolutionizing the field of lung transplantation, particularly in the United Kingdom. By enabling the assessment, repair, and optimization of marginal lungs—organs that would otherwise be deemed unsuitable for transplantation—EVLP is expanding the donor pool and saving lives.

The Challenge of Marginal Lungs

Lung transplantation is a life-saving procedure for patients with end-stage lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and cystic fibrosis. However, only about 15-20% of donated lungs are traditionally considered suitable for transplantation. Many lungs are rejected due to damage, infection, or poor function, leaving a significant portion of potential donor organs unused.

Marginal lungs, which fall outside the criteria for immediate transplantation, often have issues such as mild inflammation, fluid accumulation, or suboptimal oxygenation. Historically, these lungs were discarded due to the inability to accurately assess or improve their condition. This limitation has contributed to the organ shortage crisis, with many patients unable to receive the transplants they desperately need.

What is EVLP?

Ex Vivo Lung Perfusion (EVLP) is an innovative technology that allows donor lungs to be evaluated and treated outside the human body. The process involves placing the lungs in a sterile, temperature-controlled chamber and connecting them to a perfusion system. This system pumps a specialized solution containing oxygen, nutrients, and medications through the lungs, mimicking the conditions of the human body.

During EVLP, medical teams can monitor the lungs' function, including their ability to oxygenate blood and remove carbon dioxide. The technology also provides an opportunity to repair damage, reduce inflammation, and treat infections, effectively improving the quality of marginal lungs and making them suitable for transplantation.

EVLP in UK Hospitals: A Game-Changer

In the UK, the adoption of EVLP technology has been a game-changer for lung transplantation programs. Leading transplant centers, such as those at Royal Papworth Hospital in Cambridge and Harefield Hospital in London, have integrated EVLP into their clinical practices, with remarkable results.

1. Expanding the Donor Pool: By enabling the use of marginal lungs, EVLP has significantly increased the number of organs available for transplantation. According to NHS Blood and Transplant, the use of EVLP has contributed to a 30-40% increase in the number of lung transplants performed in the UK in recent years.

2. Improved Outcomes: Studies have shown that lungs treated with EVLP have comparable, if not better, outcomes than those transplanted without the technology. Patients who receive EVLP-treated lungs

   • Source Link: https://platohealth.ai/evlp-platform-enables-transplants-of-marginal-lungs-in-uk-hospitals/